The pill that moves the needle.

Vaxart Meeting with FDA in Q2 2024 to Discuss Potential Next Steps for Norovirus Program
0:15
Vaxart Meeting with FDA in Q2 2024 to Discuss Potential Next Steps for Norovirus Program
Vaxart Expecting Topline Results from Phase 1 Norovirus Trial in Mid-2024
0:37
Vaxart Expecting Topline Results from Phase 1 Norovirus Trial in Mid-2024
Data is Promising for Vaxart's Oral Norovirus Vaccine Candidate
0:25
Data is Promising for Vaxart's Oral Norovirus Vaccine Candidate
Vaxart Made Significant Progress on Norovirus Program in 2023
0:22
Vaxart Made Significant Progress on Norovirus Program in 2023
Data Publication Demonstrates Potential of Vaxart's COVID-19 Vaccine Candidates
0:31
Data Publication Demonstrates Potential of Vaxart's COVID-19 Vaccine Candidates
Vaxart Preparing to Initiate Phase 2b Trial of Its SARS-CoV-2 Oral Vaccine Candidate.
0:41
Vaxart Preparing to Initiate Phase 2b Trial of Its SARS-CoV-2 Oral Vaccine Candidate.
CEO Steve Lo Brings Wealth of Biopharma Experience
0:31
CEO Steve Lo Brings Wealth of Biopharma Experience
Making Steady Progress on Vaxart's Norovirus Program
0:18
Making Steady Progress on Vaxart's Norovirus Program
Vaxart Poised to Make Major Strides Forward
0:33
Vaxart Poised to Make Major Strides Forward
Vaxart Among a Select Group to Receive Project NextGen Funding
0:23
Vaxart Among a Select Group to Receive Project NextGen Funding
Vaxart Believes It Has Most Advanced Oral Norovirus Vaccine Candidate in Clinical Development
0:22
Vaxart Believes It Has Most Advanced Oral Norovirus Vaccine Candidate in Clinical Development
Vaxart's Oral Pill Vaccines May Offer Several Advantages Over Injectables
0:29
Vaxart's Oral Pill Vaccines May Offer Several Advantages Over Injectables
2023 Was a Transformational Year for Vaxart
0:30
2023 Was a Transformational Year for Vaxart
Vaxart's norovirus vaccine trials: strong immune responses
0:14
Vaxart's norovirus vaccine trials: strong immune responses
Vaxart's oral pill norovirus vaccine candidate has great potential
0:19
Vaxart's oral pill norovirus vaccine candidate has great potential
Timeline nearing for Phase 2 GI.1 norovirus challenge study
0:24
Timeline nearing for Phase 2 GI.1 norovirus challenge study
Totality of data to inform next steps for Vaxart's norovirus vaccine candidate
0:20
Totality of data to inform next steps for Vaxart's norovirus vaccine candidate
Positive Phase 2 topline results for bivalent norovirus candidate
0:30
Positive Phase 2 topline results for bivalent norovirus candidate
Significant second quarter progress
0:21
Significant second quarter progress
Vaxart founder Dr. Tucker explains why Vaxart may be able to create a pan-betacoronavirus vaccine.
0:35
Vaxart founder Dr. Tucker explains why Vaxart may be able to create a pan-betacoronavirus vaccine.
Data from Vaxart studies demonstrates its vaccine platform's ability to block COVID-19 transmission
0:44
Data from Vaxart studies demonstrates its vaccine platform's ability to block COVID-19 transmission
Vaxart continues to believe in the potential of its bivalent norovirus candidate
0:19
Vaxart continues to believe in the potential of its bivalent norovirus candidate
Vaxart's bivalent norovirus vaccine candidate has many broad advantages
0:58
Vaxart's bivalent norovirus vaccine candidate has many broad advantages
Vaxart's Oral Vaccine Platform Intends to Provide Mucosal Immunity
1:49
Vaxart's Oral Vaccine Platform Intends to Provide Mucosal Immunity
Vaxart | Duke-University-led study
1:01
Vaxart | Duke-University-led study
Vaxart | First & only COVID oral tablet vaccine that has entered phase II clinical trials
1:01
Vaxart | First & only COVID oral tablet vaccine that has entered phase II clinical trials
Nobody likes getting a shot
1:21
Nobody likes getting a shot
Vaxart Variants 2021
1:30
Vaxart Variants 2021
Vaxart Norovirus 2021
1:03
Vaxart Norovirus 2021
Vaxart Great Science 2021
1:16
Vaxart Great Science 2021